FT576 in Subjects With Multiple Myeloma

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-10-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjects withcellantibodypriortherapy
  Phrases that lowered it: receiptdaymyelomadoseperiod
• Sponsor's past termination rate: 42.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 21.9% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 5 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports before start: 193562 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 24803 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 92.9% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• FT538 in Subjects With Advanced Hematologic Malignancies NCT04614636 · started 2020 · scored riskier than 71% of active trials terminated
• A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) NCT02431208 · started 2015 · scored riskier than 23% of active trials completed
• First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) NCT04083534 · started 2019 · scored riskier than 43% of active trials completed
• Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies NCT01084252 · started 2010 · scored riskier than 26% of active trials completed
• Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma NCT03477539 · started 2018 · scored riskier than 82% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.